|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F,
Hora M, Kuczyk MA, et al: European association of urology
guidelines on renal cell carcinoma: The 2019 update. Eur Urol.
75:799–810. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong MCS, Goggins WB, Yip BHK, Fung FDH,
Leung C, Fang Y, Wong SYS and Ng CF: Incidence and mortality of
kidney cancer: Temporal patterns and global trends in 39 countries.
Sci Rep. 7:156982017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Padala SA and Barsouk A, Thandra KC,
Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A:
Epidemiology of renal cell carcinoma. World J Oncol. 11:79–87.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williamson TJ, Pearson JR, Ischia J,
Bolton DM and Lawrentschuk N: Guideline of guidelines: Follow-up
after nephrectomy for renal cell carcinoma. BJU Int. 117:555–562.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jamil ML, Keeley J, Sood A, Dalela D,
Arora S, Peabody JO, Trinh QD, Menon M, Rogers CG and Abdollah F:
Long-term risk of recurrence in surgically treated renal cell
carcinoma: A post hoc analysis of the eastern cooperative oncology
group-American college of radiology imaging network E2805 trial
cohort. Eur Urol. 77:277–281. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Unverzagt S, Moldenhauer I, Nothacker M,
Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F and Seliger B:
Immunotherapy for metastatic renal cell carcinoma. Cochrane
Database Syst Rev. 5:CD0116732017.PubMed/NCBI
|
|
12
|
Meyer E, Pasquier D, Bernadou G, Calais G,
Maroun P, Bossi A, Theodore C, Albiges L, Stefan D, de Crevoisier
R, et al: Stereotactic radiation therapy in the strategy of
treatment of metastatic renal cell carcinoma: A study of the getug
group. Eur J Cancer. 98:38–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsuji G, Ito T, Chiba T, Mitoma C,
Nakahara T, Uchi H and Furue M: The role of the OVOL1-OVOL2 axis in
normal and diseased human skin. J Dermatol Sci. 90:227–231. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar A, Bhandari A, Sinha R, Sardar P,
Sushma M, Goyal P, Goswami C and Grapputo A: Molecular phylogeny of
OVOL genes illustrates a conserved C2H2 zinc finger domain coupled
by hypervariable unstructured regions. PLoS One. 7:e393992012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Watanabe K, Villarreal-Ponce A, Sun P,
Salmans ML, Fallahi M, Andersen B and Dai X: Mammary morphogenesis
and regeneration require the inhibition of EMT at terminal end buds
by Ovol2 transcriptional repressor. Dev Cell. 29:59–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roca H, Hernandez J, Weidner S, McEachin
RC, Fuller D, Sud S, Schumann T, Wilkinson JE, Zaslavsky A, Li H,
et al: Transcription factors OVOL1 and OVOL2 induce the mesenchymal
to epithelial transition in human cancer. PLoS One. 8:e767732013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang ZH, Li Z, Hu M, Yang QJ, Yan S, Wu
RS, Li BA and Guo M: Ovol2 gene inhibits the
epithelial-to-mesenchymal transition in lung adenocarcinoma by
transcriptionally repressing Twist1. Gene. 600:1–8. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia D, Jolly MK, Boareto M, Parsana P,
Mooney SM, Pienta KJ, Levine H and Ben-Jacob E: OVOL guides the
epithelial-hybrid-mesenchymal transition. Oncotarget.
6:15436–15448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jolly MK, Jia D, Boareto M, Mani SA,
Pienta KJ, Ben-Jacob E and Levine H: Coupling the modules of EMT
and stemness: A tunable ‘stemness window’ model. Oncotarget.
6:25161–25174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nieto MA: The ins and outs of the
epithelial to mesenchymal transition in health and disease. Annu
Rev Cell Dev Biol. 27:347–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Wu Q, Wang Y, Wei Y, Wu H, Duan L,
Zhang Q and Wu Y: Ovol2 induces mesenchymal-epithelial transition
via targeting ZEB1 in osteosarcoma. Onco Targets Ther.
11:2963–2973. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu C, Yan T and Yang J: OVOL1 inhibits
oral squamous cell carcinoma growth and metastasis by suppressing
zinc finger E-box binding homeobox 1. Int J Clin Exp Pathol.
12:2801–2808. 2019.PubMed/NCBI
|
|
23
|
Qi XK, Han HQ, Zhang HJ, Xu M, Li L, Chen
L, Xiang T, Feng QS, Kang T, Qian CN, et al: OVOL2 links stemness
and metastasis via fine-tuning epithelial-mesenchymal transition in
nasopharyngeal carcinoma. Theranostics. 8:2202–2216. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mermel CH, Schumacher SE, Hill B, Meyerson
ML, Beroukhim R and Getz G: GISTIC2.0 facilitates sensitive and
confident localization of the targets of focal somatic copy-number
alteration in human cancers. Genome Biol. 12:R412011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu CJ, Hu FF, Xia MX, Han L, Zhang Q and
Guo AY: GSCALite: A web server for gene set cancer analysis.
Bioinformatics. 34:3771–3772. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
The Gene Ontology Consortium, . The gene
ontology resource: 20 years and still GOing strong. Nucleic Acids
Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu H, Qi L, Chen L, He Y, Zhang N and Guo
H: Expression of ovol2 is related to epithelial characteristics and
shows a favorable clinical outcome in hepatocellular carcinoma.
Onco Targets Ther. 9:5963–5973. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan C, Wang Q, van der Zon G, Ren J,
Agaser C, Slieker RC, Iyengar PV, Mei H and Ten Dijke P: OVOL1
inhibits breast cancer cell invasion by enhancing the degradation
of TGF-beta type I receptor. Signal Transduct Target Ther.
7:1262022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mitoma C, Nakahara T, Uchi H, Ito T,
Inatomi Y, Ide T, Jinnai S, Jinnai N, Iwasaki N, Sakamoto K, et al:
Preferential expression of OVOL1 in inner root sheath of hair,
sebaceous gland, eccrine duct and their neoplasms in human skin.
Fukuoka Igaku Zasshi. 105:166–173. 2014.PubMed/NCBI
|
|
38
|
Li J, Yu T, Cao J, Liu L, Liu Y, Kong HW,
Zhu MX, Lin HC, Chu DD, Yao M and Yan MX: MicroRNA-148a suppresses
invasion and metastasis of human non-small-cell lung cancer. Cell
Physiol Biochem. 37:1847–1856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang R, Geng GJ, Guo JG, Mi YJ, Zhu XL,
Li N, Liu HM, Lin JF, Wang JW, Zhao G, et al: An NF-κB/OVOL2
circuit regulates glucose import and cell survival in non-small
cell lung cancer. Cell Commun Signal. 20:402022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ye GD, Sun GB, Jiao P, Chen C, Liu QF,
Huang XL, Zhang R, Cai WY, Li SN, Wu JF, et al: OVOL2, an inhibitor
of WNT signaling, reduces invasive activities of human and mouse
cancer cells and is down-regulated in human colorectal tumors.
Gastroenterology. 150:659–671.e16. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu RS, Lin J, Xing YM, Gao WL, Jiang YX,
Chen LX, Zhang XP and Dai ZL: OVOL2 inhibits macrophage M2
polarization by regulating IL-10 transcription, and thus inhibits
the tumor metastasis by modulating the tumor microenvironment.
Immunol Lett. 242:17–26. 2022. View Article : Google Scholar : PubMed/NCBI
|
